New Pancreatic Cancer Drug Reduces Risk of Death by 60 Percent (2026 Update)
Daraxonrasib (RMC-6236) nearly doubles median survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) with a 60% reduction in death risk. Learn about the breakthrough RAS(ON) inhibitor, side effects, trial results, cost concerns, and what it means for patients in 2026. Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival rate under 13% overall and just 3% for metastatic disease. But in May 2026, a new oral pill called daraxonrasib (also known as RMC-6236) delivered what experts are calling “historic” and “practice-changing” results.In the pivotal Phase 3 RASolute 302 trial, daraxonrasib doubled median overall survival and cut the risk of death by 60% compared to standard chemotherapy — all while being better tolerated for many patients. Here’s everything you need to know about this groundbreaking pancreatic cancer treatment, including the science, real-world implications, side effects, cost debates, and expert perspectives. What ...